Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia UdeA, Medellín, Colombia.
National HIV and Retrovirology Laboratory, JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
PLoS One. 2019 Sep 24;14(9):e0222878. doi: 10.1371/journal.pone.0222878. eCollection 2019.
Mucosal immune activation, in the context of sexual transmission of HIV-1 infection, is crucial, as the increased presence of activated T cells enhance susceptibility to infection. In this regard, it has been proposed that immunomodulatory compounds capable of modulating immune activation, such as Vitamin D (VitD) may reduce HIV-1 transmission and might be used as a safe and cost-effective strategy for prevention. Considering this, we examined the in vitro effect of the treatment of peripheral blood mononuclear cells (PBMCs) with the active form of VitD, calcitriol, on cellular activation, function and susceptibility of CD4+ T cells to HIV-1 infection.
We treated PBMCs from healthy HIV unexposed individuals (Co-HC) and frequently exposed, HIV-1 seronegative individuals (HESNs) from Colombia and from healthy non-exposed individuals from Canada (Ca-HC) with calcitriol and performed in vitro HIV-1 infection assays using X4- and R5-tropic HIV-1 strains respectively. In addition, we evaluated the activation and function of T cells and the expression of viral co-receptors, and select antiviral genes following calcitriol treatment.
Calcitriol reduced the frequency of infected CD4+ T cells and the number of viral particles per cell, for both, X4- and R5-tropic viruses tested in the Co-HC and the Ca-HC, respectively, but not in HESNs. Furthermore, in the Co-HC, calcitriol reduced the frequency of polyclonally activated T cells expressing the activation markers HLA-DR and CD38, and those HLA-DR+CD38-, whereas increased the subpopulation HLA-DR-CD38+. Calcitriol treatment also decreased production of granzyme, IL-2 and MIP-1β by T cells and increased the transcriptional expression of the inhibitor of NF-kB and the antiviral genes cathelicidin (CAMP) and APOBEC3G in PBMCs from Co-HC.
Our in vitro findings suggest that VitD treatment could reduce HIV-1 transmission through a specific modulation of the activation levels and function of T cells, and the production of antiviral factors. In conclusion, VitD remains as an interesting potential strategy to prevent HIV-1 transmission that should be further explored.
在 HIV-1 感染的性传播过程中,黏膜免疫激活至关重要,因为激活的 T 细胞增多会增加感染的易感性。在这方面,有人提出,能够调节免疫激活的免疫调节化合物,如维生素 D(VitD),可能会降低 HIV-1 的传播,并且可以作为一种安全且具有成本效益的预防策略。考虑到这一点,我们研究了用活性形式的 VitD,即钙三醇,处理外周血单核细胞(PBMC)对 CD4+T 细胞的细胞激活、功能和对 HIV-1 感染易感性的体外影响。
我们用钙三醇处理来自哥伦比亚的健康 HIV 未暴露个体(Co-HC)和经常接触、HIV-1 血清阴性个体(HESN)以及来自加拿大的健康未暴露个体(Ca-HC)的 PBMC,并分别使用 X4-和 R5-嗜性 HIV-1 株进行体外 HIV-1 感染测定。此外,我们在钙三醇处理后评估了 T 细胞的激活和功能以及病毒共受体的表达和选择抗病毒基因。
钙三醇降低了 Co-HC 和 Ca-HC 中分别测试的 X4-和 R5-嗜性病毒感染的 CD4+T 细胞的频率和每个细胞的病毒颗粒数,但在 HESN 中没有。此外,在 Co-HC 中,钙三醇降低了表达激活标志物 HLA-DR 和 CD38 的多克隆激活 T 细胞的频率,以及 HLA-DR+CD38-,而增加了 HLA-DR-CD38+亚群。钙三醇处理还降低了 T 细胞中 granzyme、IL-2 和 MIP-1β的产生,并增加了 PBMC 中 NF-kB 抑制剂和抗病毒基因 cathelicidin(CAMP)和 APOBEC3G 的转录表达。
我们的体外研究结果表明,VitD 治疗可能通过特异性调节 T 细胞的激活水平和功能以及抗病毒因子的产生来降低 HIV-1 的传播。总之,VitD 仍然是预防 HIV-1 传播的一个有趣的潜在策略,值得进一步探索。